These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 37925432)

  • 1. Integrated machine learning identifies epithelial cell marker genes for improving outcomes and immunotherapy in prostate cancer.
    Zhu W; Zeng H; Huang J; Wu J; Wang Y; Wang Z; Wang H; Luo Y; Lai W
    J Transl Med; 2023 Nov; 21(1):782. PubMed ID: 37925432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative multi-omics analysis unveils stemness-associated molecular subtypes in prostate cancer and pan-cancer: prognostic and therapeutic significance.
    Zheng K; Hai Y; Xi Y; Zhang Y; Liu Z; Chen W; Hu X; Zou X; Hao J
    J Transl Med; 2023 Nov; 21(1):789. PubMed ID: 37936202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of metastasis-related genes for predicting prostate cancer diagnosis, metastasis and immunotherapy drug candidates using machine learning approaches.
    Wang Y; Ji B; Zhang L; Wang J; He J; Ding B; Ren M
    Biol Direct; 2024 Jun; 19(1):50. PubMed ID: 38918844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disulfidptosis-related genes serve as potential prognostic biomarkers and indicate tumor microenvironment characteristics and immunotherapy response in prostate cancer.
    Zhou R; Lu D; Mi J; Wang C; Lu W; Wang Z; Li X; Wei C; Zhang H; Ji J; Zhang Y; Zhang D; Wang F
    Sci Rep; 2024 Jun; 14(1):14107. PubMed ID: 38898043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel ferroptosis-related gene prognostic index for prognosis and response to immunotherapy in patients with prostate cancer.
    Wang Y; Fan J; Chen T; Xu L; Liu P; Xiao L; Wu T; Zhou Q; Zheng Q; Liu C; Chan FL; Wu D
    Front Endocrinol (Lausanne); 2022; 13():975623. PubMed ID: 36034466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prognostic signature consisting of metabolism-related genes and SLC17A4 serves as a potential biomarker of immunotherapeutic prediction in prostate cancer.
    Li H; Gu J; Tian Y; Li S; Zhang H; Dai Z; Wang Z; Zhang N; Peng R
    Front Immunol; 2022; 13():982628. PubMed ID: 36325340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A machine learning framework develops a DNA replication stress model for predicting clinical outcomes and therapeutic vulnerability in primary prostate cancer.
    Huang RH; Hong YK; Du H; Ke WQ; Lin BB; Li YL
    J Transl Med; 2023 Jan; 21(1):20. PubMed ID: 36635710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated multi-omics analysis and machine learning identify hub genes and potential mechanisms of resistance to immunotherapy in gastric cancer.
    Wang J; Feng J; Chen X; Weng Y; Wang T; Wei J; Zhan Y; Peng M
    Aging (Albany NY); 2024 Apr; 16(8):7331-7356. PubMed ID: 38656888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-omics analysis reveals a macrophage-related marker gene signature for prognostic prediction, immune landscape, genomic heterogeneity, and drug choices in prostate cancer.
    Zhu W; Wu J; Huang J; Xiao D; Li F; Wu C; Li X; Zeng H; Zheng J; Lai W; Wen X
    Front Immunol; 2023; 14():1122670. PubMed ID: 37122696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-cell and bulk RNA sequencing reveal cancer-associated fibroblast heterogeneity and a prognostic signature in prostate cancer.
    Liu W; Wang M; Wang M; Liu M
    Medicine (Baltimore); 2023 Aug; 102(32):e34611. PubMed ID: 37565899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-omics analysis and experimental validation of the value of monocyte-associated features in prostate cancer prognosis and immunotherapy.
    Wang Y; Li C; He J; Zhao Q; Zhou Y; Sun H; Zhu H; Ding B; Ren M
    Front Immunol; 2024; 15():1426474. PubMed ID: 38947325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma cell subtypes analyzed using artificial intelligence algorithm for predicting biochemical recurrence, immune escape potential, and immunotherapy response of prostate cancer.
    Xie X; Dou CX; Luo MR; Zhang K; Liu Y; Zhou JW; Huang ZP; Xue KY; Liang HY; Ouyang AR; Ma SX; Yang JK; Zhou QZ; Guo WB; Liu CD; Zhao SC; Chen MK
    Front Immunol; 2022; 13():946209. PubMed ID: 36569837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The established chemokine-related prognostic gene signature in prostate cancer: Implications for anti-androgen and immunotherapies.
    Chen L; Zheng Y; Jiang C; Yang C; Zhang L; Liang C
    Front Immunol; 2022; 13():1009634. PubMed ID: 36275733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
    Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
    BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated analysis of single-cell and bulk RNA sequencing identifies a signature based on macrophage marker genes involved in prostate cancer prognosis and treatment responsiveness.
    Li X; Zheng C; Xue X; Wu J; Li F; Song D; Li X
    Funct Integr Genomics; 2023 Apr; 23(2):115. PubMed ID: 37010617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing.
    Li T; Zhou Z; Xie Z; Fan X; Zhang Y; Zhang Y; Song X; Ruan Y
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11379-11395. PubMed ID: 37369799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Machine learning-derived identification of prognostic signature for improving prognosis and drug response in patients with ovarian cancer.
    Huan Q; Cheng S; Ma HF; Zhao M; Chen Y; Yuan X
    J Cell Mol Med; 2024 Jan; 28(1):e18021. PubMed ID: 37994489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of machine learning-based integration to develop an immune-related signature for improving prognosis in patients with gastric cancer.
    Ning J; Sun K; Fan X; Jia K; Meng L; Wang X; Li H; Ma R; Liu S; Li F; Wang X
    Sci Rep; 2023 Apr; 13(1):7019. PubMed ID: 37120631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MT1G, an emerging ferroptosis-related gene: A novel prognostic biomarker and indicator of immunotherapy sensitivity in prostate cancer.
    Cheng B; Lai Y; Huang H; Peng S; Tang C; Chen J; Luo T; Wu J; He H; Wang Q; Huang H
    Environ Toxicol; 2024 Feb; 39(2):927-941. PubMed ID: 37972062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Microenvironment and Response in Prostate Cancer Using Large Population Cohorts.
    Ren X; Chen X; Zhang X; Jiang S; Zhang T; Li G; Lu Z; Zhang D; Wang S; Qin C
    Front Immunol; 2021; 12():686809. PubMed ID: 34777331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.